LAUSR

in relation to guidelines, for example NCCN, recommend whole-body 11C-Choline-PET/CT in patients with BCR after primary treatment failure. These new techniques are a great advance for the management of these patients. Its superiority lies in the ability to detect early tumor cells in the hematopoietic compartment, also demonstrating greater sensitivity for the early detection of metastases. This causes a high affinity to tumor cells, long before morphological changes take place. However, despite the advantage of metabolic techniques compared to conventional morphological techniques, the same as occured in castration-resistant prostate cancer patients [4], not all clinical guidelines are used as the techniques of choice in the management of these patients and not all hospital have these equipments. This can translate an unequal management of patients and raises if we are using modern treatments with a high impact in the survival of these patients, but we are using conventional techniques in the diagnosis of metastasis, with lower detection rates when compared with modern imaging techniques. Therefore, the discrepancy in the management of the detection of metastasis would have to make us think if we are using in our clinical practice the most appropriate in patients with prostate cancer.